By: Adam Feuerstein | 08/01/14 - 11:11 AM EDT
another patient enrollment update Friday for its Multikine phase III study in head-and-neck cancer. Unfortunately, the company's math is wildly optimistic.
Over the last three months, Cel-Sci enrolled 47 patients into the study. This prompted Cel-Sci CEO Geert Kersten to make the following prediction:
We reached an important milestone in July with total patient enrollment reaching 232, which is over one-quarter of the total 880 patients we expect to enroll by the end of 2015. We are on track with the pace of enrollment, which should accelerate in the fall based on the increasing number of clinical centers joining our study.It's a slow summer Friday, so let's have fun with math.
12/19/14 - 04:16 PM EST
12/19/14 - 08:25 AM EST
12/16/14 - 11:20 AM EST
12/15/14 - 09:23 AM EST
12/03/14 - 04:01 PM EST
12/26/14 - 09:49 AM EST
12/24/14 - 08:45 AM EST
12/23/14 - 10:03 AM EST
12/23/14 - 06:07 AM EST
12/22/14 - 09:11 AM EST
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.